Pfizer Inc.'s shares (NYSE:PFE) have gained attention from investors and analysts, stirring uncertainty about the stock's future. Investors are reportedly wary about Pfizer, leading some to short sell. The company showed robust Q4 performance, heightening investor interest, despite concerns over sustainability. Several firms, including AustralianSuper Pty Ltd and Jefferies, increased their stakes or projections while some others, like Villere ST Denis J & CO. LLC and Rhumbline Advisers, reduced holdings. Despite a promising Q4 report, PFE shares fell due to market volatility. Pfizer has been able to dodge a proxy fight with activist investor Starboard, at least temporarily. Some consider Pfizer to be a safe stock, offering steady dividends and low-risk for long-term investment. Pfizer's Q4 beat revenue and earnings predictions, which may speed up growth, according to analysts. The company gets a favorable evaluation from pundits, including a 'buy' rating from Guggenheim and Jim Cramer backing the stock. Regardless, PFE is contending with challenges such as overvaluation and the escalating competition in the vaccine market.
Pfizer Stocks News Analytics from Mon, 14 Oct 2024 07:00:00 GMT to Sat, 15 Feb 2025 23:51:11 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 4
